User login
The line-up for David Henry’s monthly podcast for The Journal of Community and Supportive Oncology includes an Original Report in which investigators report complete response rates (no emesis, no rescue medication) APF530, a sustained-release granisetron, during the acute and delayed phases of chemotherapy-induced nausea and vomiting over multiple cycles of the therapy. He also discusses the findings from a study on joint breast and colorectal cancer screenings in medically underserved women, and another in women with self-reported lower limb lymphedema after treatment for gynecological cancers and their use of services. A fourth Original Report examines perceptions about participation in cancer clinical trials in New York state and how increased outreach and a team approach to educating and enrolling patients in trials are important to increase participation and ensure a diverse sample of participants. Finally, a feature article on new therapies looks at the significant challenges – and recent advances – in the treatment of head and neck cancers.
The line-up for David Henry’s monthly podcast for The Journal of Community and Supportive Oncology includes an Original Report in which investigators report complete response rates (no emesis, no rescue medication) APF530, a sustained-release granisetron, during the acute and delayed phases of chemotherapy-induced nausea and vomiting over multiple cycles of the therapy. He also discusses the findings from a study on joint breast and colorectal cancer screenings in medically underserved women, and another in women with self-reported lower limb lymphedema after treatment for gynecological cancers and their use of services. A fourth Original Report examines perceptions about participation in cancer clinical trials in New York state and how increased outreach and a team approach to educating and enrolling patients in trials are important to increase participation and ensure a diverse sample of participants. Finally, a feature article on new therapies looks at the significant challenges – and recent advances – in the treatment of head and neck cancers.
The line-up for David Henry’s monthly podcast for The Journal of Community and Supportive Oncology includes an Original Report in which investigators report complete response rates (no emesis, no rescue medication) APF530, a sustained-release granisetron, during the acute and delayed phases of chemotherapy-induced nausea and vomiting over multiple cycles of the therapy. He also discusses the findings from a study on joint breast and colorectal cancer screenings in medically underserved women, and another in women with self-reported lower limb lymphedema after treatment for gynecological cancers and their use of services. A fourth Original Report examines perceptions about participation in cancer clinical trials in New York state and how increased outreach and a team approach to educating and enrolling patients in trials are important to increase participation and ensure a diverse sample of participants. Finally, a feature article on new therapies looks at the significant challenges – and recent advances – in the treatment of head and neck cancers.